Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study

Figure 3

Histological assessment of minor salivary gland biopsies. (A), (B) Histological scoring of minor salivary gland (MSG) biopsies in the rituximab (RTX) and disease-modifying anti-rheumatic drug (DMARD) treatment groups at baseline and week 120. (C), (D) Percentage of CXCR4-positive cells and CXCR5-positive cells inside the glandular infiltrate. Bars indicate mean ± standard error of the mean. ***P <0.001, **P <0.01 and *P <0.05. (E) Percentage of patients displaying germinal centers (GCs) in the RTX and DMARD treatment groups at baseline and week 120. MNC, mononuclear cells.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us